AMG National Trust Bank continued to hold its stake in shares of AxoGen, Inc. (NASDAQ:AXGN) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 15,965 shares of the medical equipment provider’s stock at the end of the second quarter. AMG National Trust Bank’s holdings in AxoGen were worth $267,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently made changes to their positions in AXGN. Teachers Advisors LLC raised its position in AxoGen by 25.5% during the fourth quarter. Teachers Advisors LLC now owns 48,740 shares of the medical equipment provider’s stock valued at $439,000 after purchasing an additional 9,893 shares in the last quarter. Bank of Montreal Can raised its position in AxoGen by 978.5% during the first quarter. Bank of Montreal Can now owns 14,981 shares of the medical equipment provider’s stock valued at $157,000 after purchasing an additional 13,592 shares in the last quarter. TFS Capital LLC acquired a new position in AxoGen during the first quarter valued at approximately $120,000. Parametric Portfolio Associates LLC raised its position in AxoGen by 0.9% during the first quarter. Parametric Portfolio Associates LLC now owns 10,843 shares of the medical equipment provider’s stock valued at $113,000 after purchasing an additional 93 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC raised its position in AxoGen by 3.2% during the first quarter. Campbell & CO Investment Adviser LLC now owns 11,055 shares of the medical equipment provider’s stock valued at $116,000 after purchasing an additional 341 shares in the last quarter. Institutional investors and hedge funds own 66.77% of the company’s stock.
In other news, Director Robert James Rudelius sold 16,143 shares of AxoGen stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $18.00, for a total transaction of $290,574.00. Following the completion of the transaction, the director now directly owns 43,273 shares of the company’s stock, valued at approximately $778,914. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 9.33% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: “AMG National Trust Bank Has $267,000 Stake in AxoGen, Inc. (NASDAQ:AXGN)” was originally posted by BBNS and is the property of of BBNS. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://baseballnewssource.com/markets/amg-national-trust-bank-has-267000-holdings-in-axogen-inc-axgn/1601412.html.
Shares of AxoGen, Inc. (NASDAQ:AXGN) opened at 18.60 on Friday. The firm’s market cap is $618.26 million. The company has a 50 day moving average of $16.58 and a 200-day moving average of $14.19. AxoGen, Inc. has a 12-month low of $7.65 and a 12-month high of $19.20.
AxoGen (NASDAQ:AXGN) last announced its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.02. The business had revenue of $15.20 million during the quarter, compared to analysts’ expectations of $14.40 million. AxoGen had a negative net margin of 27.50% and a negative return on equity of 114.64%. The business’s quarterly revenue was up 46.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.09) EPS. Analysts predict that AxoGen, Inc. will post ($0.31) EPS for the current year.
Several research analysts have recently issued reports on the stock. Roth Capital reiterated a “buy” rating and set a $21.00 price target (up from $18.00) on shares of AxoGen in a report on Tuesday, September 12th. BidaskClub downgraded shares of AxoGen from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $18.00 price target on shares of AxoGen in a research report on Monday, August 21st. Leerink Swann assumed coverage on shares of AxoGen in a research report on Monday, July 31st. They set an “outperform” rating and a $22.00 price target on the stock. Finally, ValuEngine raised shares of AxoGen from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. AxoGen has an average rating of “Buy” and a consensus price target of $17.20.
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with our FREE daily email newsletter.